Background There are substantial advances in diagnosis and treatment for idiopathic
pulmonary fibrosis (IPF), but without much evidence available on recent mortality and …

It is known that the cell environment such as biomechanical properties and extracellular
matrix (ECM) composition dictate cell behaviour including migration, proliferation, and …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity
and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung …

Background Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple
comorbidities, which may influence survival but go under-recognised in clinical practice. We …

Background Idiopathic pulmonary fibrosis is a progressive fibrotic lung disease with a
variable clinical trajectory. Decline in forced vital capacity (FVC) is the main indicator of …

Survival analysis is a valuable tool for estimating the time until specific events, such as death
or cancer recurrence, based on baseline observations. This is particularly useful in …

Purpose Real-world studies have reported reduced mortality in patients with idiopathic
pulmonary fibrosis (IPF) treated with antifibrotic therapy; however, the initiation or …

Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung
disease characterised by decline in lung function. We evaluated trajectories of forced vital …

Background Disease heterogeneity in idiopathic pulmonary fibrosis (IPF) often complicates
the systematic study of disease, management of patients and clinical investigations …

Background and objective Antifibrotic therapy with nintedanib or pirfenidone slows disease
progression and reduces mortality in patients with idiopathic pulmonary fibrosis (IPF) …